13/09/2021
Marie Skłodowska-Curie Actions

One Early Stage Researcher (PhD students) position at the University of Padova within the framework of the MSCA-ITN project: “Directing the immune response through designed nanomaterials” (DIRNANO)

This job offer has expired


  • ORGANISATION/COMPANY
    University of Padua
  • RESEARCH FIELD
    Biological sciences
    Medical sciences
    Pharmacological sciences
    TechnologyBiotechnology
    TechnologyChemical technology
  • RESEARCHER PROFILE
    First Stage Researcher (R1)
  • APPLICATION DEADLINE
    15/11/2021 13:00 - Europe/Brussels
  • LOCATION
    Italy › Padova
  • TYPE OF CONTRACT
    Temporary
  • JOB STATUS
    Full-time
  • HOURS PER WEEK
    40
  • OFFER STARTING DATE
    01/01/2022
  • EU RESEARCH FRAMEWORK PROGRAMME
    H2020 / Marie Skłodowska-Curie Actions
  • MARIE CURIE GRANT AGREEMENT NUMBER
    956544

OFFER DESCRIPTION

One ESR position (PhD) is now available at the University of Padova (Italy), within theframework of the Maria Skłodowska-Curie Innovative Training Network (MSCA-ITN) project “Directing the immune response through designed nanomaterials"- DIRNANO.

Hosting department: 

ESR position (code ESR02): Department of Biomedical Sciences.

 

WARNING: if you wish to apply, please remember to upload the file named "Application form" (available here: ALBO DIPARTIMENTO DI SCIENZE BIOMEDICHE) duly signed and dated. The application form should be uploaded in the section "Other Attachments" of the online procedure that starts in this job vacancy at the section "where to apply".

 

ESR02- Overview of the hosting Department and Individual research project.

The scientific activities of the Department of Biomedical Sciences (DBS) of the University of Padova (Italy) (http://www.biomed.unipd.it/), launched on March 1, 1992, focus on those major different and complementary aspects of cellular and molecular biology, cell physiology, molecular pathology and experimental pharmacology having implications for genetics diseases and degenerative, inflammatory processes, malignancies and their diagnosis/cure perspectives on a molecular-based ground. The research on the many physio-pathological multifaceted effects, implications and mechanisms of the newly emerged integrated discipline of NANO(BIO)MEDICINE gained its place within the general investigation milieu of the Department in the past decades, and is steadily progressing in the departmental scientific area dedicated to Medical Biotechnology.

One ESR position (ESR02) is now available at the Department of Biomedical Sciences.

The ESR2 of NANO-BIOTECHNOLOGY AND NANO-BIOMEDICINE of the DBS, led by Prof. Emanuele Papini, and the Marie Skłodowska - Curie Innovative Training Network (MSCA-ITN) project “DIRNANO - Directing the immune response through designed nanomaterials” OFFERS an Early Stage Researcher (PhD Student) position:

ESR02 - "Protein composition and functional effects of the species-specific biomolecular corona formation on NPs”.

-This PhD project will focus on the full characterization of the interaction between host macromolecules and consortium-generated NPs in host fluids to understand their influence on NP bioactivity and efficacy.

-This will be done in closely related mammalian species used as preclinical models (e.g. mouse and pigs), which evolved differentiated reactivity and organization of Complement and other innate mechanisms, which could negatively impact extrapolations to the human being.

-The goal of this ESR is extensively mapping the corona composition formed in human and animals’ sera, according to the coat type and evaluating Ca /Mg dependence to monitor complement activation and abundance. We will probe the effect of putative pro-opsonic agonists (e.g. collectins) with antagonists (e.g. N-acetyl-glucosamine or mannose) or compound mimicking monomers of the NP-covering polymers (e.g. N,N-dimethyl acetyl-amide in case of PMOXA coats) on NP proteome and phagocytes capture.

-The effect of anti-corona protein mab (native or engineered) or recombinant engineered coat-binding innate proteins (e.g. Ficolins, C1q) will be assayed to increase the number of conditions studied and the robustness of quantification and to considerably reduce times. After initial protein abundance screening by label-free parameters, major and functionally relevant components will be assessed by quantitative proteomics approaches or WB.

-In case of commercial antibodies lack, polyclonal/monoclonal ab will be generated by another participant to the project, the company STABVIDA.

-Recombinant antibodies-based assays will be also applied for validation, to immune -deplete sera and to test biochemical and functional effects. Modulation of the binding of specific components to a coat will be also obtained via use of known innate-recognized sugars or by using single molecules resembling the NP polymer coats unit (for example dimethyl amide for PMOXA). Phagocytosis will be quantified by FACS and confocal analysis.

Expected results of ESR02 activity:

Providing information on the major functional pro-opsonic and pro-inflammatory innate component affinity to coats type and suggesting feed-back modification of their formulation to test the possibility of its abolition (stealth) or improvement (nanovaccine). Reveal major species-specific molecular differences and point to NP characteristics showing interspecific similarity, for safer preclinical predictive power.

 

ESR02 International collaborations and secondments are foreseen in:

  1. The Department of Tumor Biology and the Department of Molecular Cell Biology of the Oslo University, Oslo, Norway (OUS, under the supervision of prof. G.M. Malandsom), to learn TAM targeting in murine models to allow training in methodologies used to assess in vivo distribution of NPs and on the evaluation of selective capture to defined TAM phenotype, month 12, 3 months.
  2. The Department of Biosciences of Paris Londron University, Salzburg, Austria (PLUS, under the supervision of prof. J. Horeis-Hoeck) to be trained on the capture analysis of macrophage related but functionally different antigen presenting cells, like DCs, month 24, 3 months.

 

The ESR02 will be employed and enrolled in the doctoral programme of Biomedical Science (PhD Biomedical Sciences) of the University of Padova.

For further information about the scientific content please contact the principal supervisor: Prof. Emanuele Papini (emanuele.papini@unipd.it and in CC dirnano.euproject@bio.unipd.it)

 

PROJECT AND CONSORTIUM DESCRIPTION

DIRNANO is a European Training Network funded by the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 956544.

The consortium comprises universities, research institutions, enterprises and partner organisations in 9 European countries (Norway, the UK, the Netherland, Spain, Portugal, Italy, the Helvetic Confederation, Austria and Hungary). This creates a novel platform for training a network of 15 Early Stage Researchers (ESRs) in the fields of nanomedicine, nanopharmacology, nanobiotechnology and nanomaterials for medical applications.

DIRNANO Scientific target: It is known that the full therapeutic potential of nanomedicines is unfulfilled due to opposing interactions with body’s defenses and adverse immune reactions. DIRNANO aims at overcoming these limitations through the comprehensive understanding of nanomaterials-host interplay and an extensive animal model testing.

We will develop strategies to map, study, modulate and exploit nanoparticle (NP)-immune interactions through core state-of-the-art approaches.

These include:

  1. inception of novel, but simple, coating engineering based on new organic polymers and conjugation chemistry, rational polymer pairing and zwitterionic lipids.
  2. engineering (with a green-chemistry approach) of libraries of host or microbial derived modulators of the innate immunity (particularly of the complement system)
  3. designing and pre-clinical testing of next generation therapeutic nanovaccines (i.e. NPs with optimized multivalent neo-antigen presentation and immunostimulatory cues) and immune- modulating NPs directly targeting tumor cells or immune suppressive cells.

 

The DIRNANO’s core-scientific training is focused on gross structure- activity profiling, integrating interfacial and chemical sciences with systems immunology for mapping of dynamic host and interfacial factors that regulate NP performance This approach will lead to rational engineering of libraries of on-demand NPs with tunable immune modulating functions Moreover, the combinatorial analysis of NP core-coat scaffold will improve our temporal and spatial understanding of biomaterial-innate immune interactions at a deeper molecular level, and potentially fill the void in overcoming adverse injection reactions to nanopharmaceuticals in sensitive individuals.

The participating teams comprise internationally renowned scientists and industrialists at the forefront of nanomedicine, immune safety, pharmaceutical sciences, green chemistry, commerce and business, where many of the participants have a proven record of accomplishment and working with each other.

ESR training and final achieved competences. The ESR will be engaged in an integrated and highly interdisciplinary approach for academic and regulatory/business training having a broader cutting-edge knowledge in translational nanomedicine bioengineering.ESRs will master immune safe-by-design and pharmaceutically viable smart-by-design approaches to lead the development of the future nanopharmaceuticals through a low-risk-high gain perspective.

ESR future mission. DIRNANO ESRs will be part of a unique pan-European macro-environment for integrated, advanced and accelerated training and circulation through open innovation and outreach activities at the highest international level, thereby contributing to the European socioeconomics and education values, skill retention and brain-gain.

 

More Information

Benefits

The salary for PhD students is based on the MSCA ITN Grant Agreement. The salary includes living allowances, mobility allowance and family allowance if eligible under the MSCA ITN rules.

Other benefits will be equal to all employees of the University of Padova.

Health insurance that entitles the Marie Skłodowska-Curie researchers to receive medical care in Italy will be guaranteed. The Department of Biomedical Sciences shall pay the related costs.

We will ensure and promote gender/based equal opportunities and non-discrimination (“Priorities and Key Actions for 2016-2019” of the EU Commissioner for Justice, Consumers and Gender Equality, the “Strategic engagement to gender equality 2016-2019” and the 2011-2020 European Pact for gender equality) and actively pursue gender balance in personnel hiring. University of Padova, as the other DIRNANO Institution, following their Statues and Ethic Codes, will fully valorise human resources independently on sex, religion and ethnic origin, promoting each person equal dignity; adopt rules against sexual harassments and mobbing; ensure equal-pay-for-equal-work-of-equal-values and equal decision-making weight for women and men in monitoring, steering, managing and any other consortium activities; grant pregnancy and new-borns cares rights, with no damages for work- position, the validity of contracts and career, according to national legislation and partners statutes, allowing ESRs to combine family and work. ESRs will enjoy the same standards and working conditions, salaries and social security contributions during parental leave applicable to local researchers with similar position and active support from hosting and PhD-awarding institutions for project advance.

Eligibility criteria

The Marie Skłodowska-Curie candidates comply with the following conditions:

Mobility rule: Have not resided in the country of the recruiting university (Italy) for more than 12 months in the 3 years immediately before the recruitment date (01 January 2022) and have not carried out their main activity (work, studies, etc.) in that country (Italy) – unless as part of a procedure for obtaining refugee status under the Geneva Convention

Early Stage Researcher: be — at the date of recruitment (01 January 2022) — an “Early Stage Researcher-ESR” (i.e. in the first four years of his/her research career and not have a doctoral degree). Years of “research career” are counted from the date on which the researcher obtained a degree entitling him/her to embark on a doctoral programme (either in the country in which it was obtained or in which s/he is recruited: Italy) — even if the doctorate was never started or envisaged.

Academic Qualification: Marie Skłodowska-Curie applicants with an academic qualification awarded in a country other than Italy can be admitted to a PhD course only if the above mentioned qualification is equivalent to a second-cycle Italian degree (“Laurea magistrale a ciclo unico”/”Laurea specialistica”/Laurea magistrale”) awarded at an officially recognized foreign academic institution, which grants admission to a PhD course in the education system/Country in which it was awarded (except for significant differences). Said qualification must be comparable to the Italian degree required for the admission to a PhD course (i.e. Master’s Degree or another equivalent second-cycle degree).

Selection process

The Candidate evaluation committee will be composed by the host beneficiary leader and two network team leaders or permanent staff team members, chosen to avoid conflicts of interest and to grant scientific expertise in the project area, contribution by different sectors (public, private, academic, non-academic), and gender balance (at least one member for each gender). If such conditions are not at reach in the network, experts from other institutions will be invited. The criteria for selection, based on submitted applications and face-to-face (Zoom) interviews of shortlisted candidates, will be candidate scientific excellence and future potential. The whole range of candidates’ hard and soft skills will be qualitatively and quantitatively evaluated. Bibliometric indices will be balanced by motivation, ambition to develop knowledge, understanding of the research theme, critical analysis and result-reporting abilities. Teamwork, public awareness activities and mobility experiences, (e.g. previous changes of country stay, work/study setting, discipline and sector) will be considered valuable candidate features.

Web site for additional job details

Offer Requirements

  • REQUIRED EDUCATION LEVEL
    Biological sciences: Master Degree or equivalent
    Pharmacological sciences: Master Degree or equivalent
    Technology: Master Degree or equivalent
  • REQUIRED LANGUAGES
    ENGLISH: Good

Skills/Qualifications

ESR02 - Protein composition and functional effects of the species-specific biomolecular corona formation on NPs”. Supervisor: Prof. Papini.

We are looking for a candidate with a MSc degree in biology, biochemistry, molecular biology, Biotechnology or similar biomedical degrees. Candidates should have the ability to work independently and in collaboration with others, and have good oral and written communication skills in English.

Specific Requirements

ESR02 - Protein composition and functional effects of the species-specific biomolecular corona formation on NPs”. Supervisor: Prof. Papini.

Experience with 1) cell isolation, culturing, handling and analysis and 2) basic biochemical approaches and protein chemistry are recommended. Experience with antibody-based tools and immune-based assays will be useful.

Work location(s)
1 position(s) available at
University of Padua
Italy
Padova
Padova
35131
Via Ugo Bassi 58/B

EURAXESS offer ID: 683329

Disclaimer:

The responsibility for the jobs published on this website, including the job description, lies entirely with the publishing institutions. The application is handled uniquely by the employer, who is also fully responsible for the recruitment and selection processes.

 

Please contact support@euraxess.org if you wish to download all jobs in XML.